InterpretOmics opens NGS facility at Bengaluru

The facility, set up at a cost of Rs 35 million, will offer genome sequencing services to R&D institutes, pharmaceuticals, biotechnology firms etc

Bengaluru-based InterpretOmics has opened a next generation sequencing (NGS) facility at Bengaluru. The facility, set up at a cost of Rs 35 million, was inaugurated recently and will offer genome sequencing services spanning to R&D institutes, pharmaceuticals, biotechnology firms, CROs and bio-agriculture companies.

Reportedly, the primary activities in this new facility would be biomarker discovery, drug target discovery, and trial stratification for biotech, pharma and CROs and genomic selection of specific traits in new crop development for bio-agriculture firms.

“The opening of this state-of-the-art facility will go a long way in providing quality services and determining company’s success moving forward,” said Dr Rajeev Soni, Senior Manager – R&D, Novozymes South Asia, who was the Guest of Honour and inaugurated the facility.

“The newly inaugurated center will cater to our growing customer base in next generation sequencing and analysis. The facility also houses a bio-bank. The focus is on research, development and delivering model (RDD). Our USP is carrying out R&D along with the delivery. InterpretOmics now has 35 professionals and plans to achieve a head count of 40 by the end of July 2015,” said Prahalad Achutharao, Co-Founder & CEO, InterpretOmics.

“Data Scientists at InterpretOmics are experts in analysing vast amount of genomic data. Our team has handled numerous complex next generation sequencing data analysis projects and processed more than 250 TB of data. With our new center for Next Generation Sequencing, we will offer both – sequencing, analysis and interpretation services and thus create comfort, convenience and credibility to our NGS clientele from industry,” said Dr Asoke Talukder, Co-Founder & CSO, InterpretOmics.